#drug pricing

Older drugs, many on the market for years, are rising in cost much faster than inflation.

These drugs, made from living organisms, are big moneymakers partly because they have little competition. It’s a different story in Europe.

“The result of this progress is that we openly talk about curing cancers that were recently fatal,” says Commissioner Gottlieb.

A recent study found that 42% of patients depleted 100 percent of their assets—an average loss of $92,000—within two years of diagnosis.

A new study examines the clinical and economic impact of new direct-acting antivirals.

Plans will be able to add restrictions on certain drugs to treat diseases like cancer, requiring patients to first try cheaper drugs.

Peter J. Pitts is president of the Center for Medicine in the Public Interest.

The approved therapies have roiled the insurance approval process, which has led to delays and denials of coverage.

Nonprescription drugs are used by consumers without the supervision of a health care professional and require a very high safety margin.

Biosimilar products can provide additional treatment options and create market competition, potentially lowering the costs of treatment.

Cross-border collaboration compared findings in British Columbia and Washington state.

We know that there are situations where that expected competition isn’t materializing in a timely manner.

It’s about time we mount a full-court press against pharmacy benefit managers’ denial of drug coverage.

Enhancing generic competition is an effective way to promote access to needed medicines.

Stocks of drug companies are rising—and that’s not a good sign for consumers.

The Community Cancer Care Report on quality and cost is the product of five years of stakeholder collaboration.